Home > Search Results

Results: 1 to 20 of 195

Serotonin and noradrenaline reuptake inhibitors for fibromyalgia

Researchers in the Cochrane Collaboration conducted a review of research about the effects of serotonin and noradrenaline reuptake inhibitors (SNRIs) on fibromyalgia syndrome (FMS). After searching for all relevant studies, they found 10 studies with up to 6038 people. Their findings are summarized below.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Selective serotonin and norepinephrine reuptake inhibitors (SNRI) for patients with depression: Executive summary of final report A05-20A, Version 1.0

The aim of this research is to assess the benefit of the selective serotonin and norepinephrine reuptake inhibitors (SNRI) venlafaxine and duloxetine in treating the acute phase of depression, in maintenance therapy (relapse prevention), and in recurrence prevention compared to treatment with placebo, treatment with other antidepressants, each other, in each case in adult patients with depression with reference to patient-relevant outcomes.

Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: June 17, 2009

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for preventing migraine

Migraine is a common condition that can significantly impair people's quality of life. Individuals who experience frequent or severe migraine may benefit from preventive medications taken prior to an attack and before the pain starts. Studies have suggested the potential role of neurotransmitters in the genesis of headache. Accordingly, drugs that inhibit the passage of neurotransmitters in brain cells and, therefore, increase their levels, have been examined for their potential benefit in preventing migraine. Two classes of inhibitors, the selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs), typically used to treat depression, are evaluated in this review.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for preventing tension‐type headache

Tension‐type headache is a common type of headache that can significantly impair people's quality of life. Individuals who experience frequent or severe headaches may benefit from medications taken before the pain starts. Two classes of medication, the selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs), typically used to treat depression, are evaluated in this review.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Dopamine versus norepinephrine for septic shock: a systematic review

Bibliographic details: Zhao Y, Wang Q, Zang B.  Dopamine versus norepinephrine for septic shock: a systematic review. Chinese Journal of Evidence-Based Medicine 2012; 12(6): 679-685 Available from: http://www.cjebm.org.cn/oa/DArticle.aspx?type=view&id=201206012

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Duloxetine can improve the quality of life of patients with stress urinary incontinence, long‐term effects of the treatment are unclear.

Stress urinary incontinence is involuntary urine leakage on coughing or exertion. The trials reviewed compared duloxetine against dummy placebo tablets and also pelvic floor muscle training in women with predominantly stress urinary incontinence. Duloxetine reduced the frequency of episodes of incontinence and improved quality of life scores. However, it had little impact on the numbers cured and commonly had side effects, especially nausea. More studies comparing a serotonin and noradrenaline reuptake inhibitor with placebo and surgery are required, especially if conducted independently of pharmaceutical companies.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Modest salt reduction lowers blood pressure in all ethnic groups at all levels of blood pressure without adverse consequences

The public health recommendations in most countries are to reduce salt intake from the current levels of approximately 9‐12 grams per day to less than 5‐6 grams per day. Our pooled analysis of randomised trials of 4 weeks or more in duration shows that such a reduction in salt intake lowers blood pressure both in individuals with raised blood pressure and in those with normal blood pressure. The fall in blood pressure is shown in both whites and blacks, men and women. Additionally, our results show that a longer‐term modest reduction in salt intake has no adverse effect on hormone and lipid levels. These findings provide further strong support for a reduction in population salt intake. This will likely lower population blood pressure and reduce strokes, heart attacks and heart failure. Furthermore, our results are consistent with the fact that the lower the salt intake, the lower the blood pressure. The current recommendations to reduce salt intake to 5‐6 grams per day will lower blood pressure, but a further reduction to 3 grams per day will lower blood pressure more. Therefore, 3 grams per day should become the long‐term target for population salt intake.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Non‐hormonal interventions for reducing hot flushes in women with a history of breast cancer

Breast cancer is one of the most frequent cancers worldwide and its treatment can produce disturbing symptoms including hot flushes, the sudden feeling of heat in the face, neck and chest. Hormonal treatments are used to control such symptoms in postmenopausal women but for women with a history of breast cancer these are not recommended as they can induce cancer growth. The aim of this review is to evaluate the efficacy of non‐hormonal interventions in treating hot flushes in such women.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2010

Do a group of drugs known as monoaminergic agonists help the brain recovery after a severe injury?

Not all of the brain damage sustained after a traumatic brain injury (TBI) is due to the direct injury that occurs at the moment of impact. Severe injury can initiate a sequence of events over several hours that can lead to secondary damage or death of brain tissue. However, the effectiveness of so‐called "neuroprotective" interventions aimed at preventing this sequence of events or minimising its harm have so far been disappointing.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis

BACKGROUND: Hepatorenal syndrome (HRS) is a severe and progressive functional renal failure occurring in patients with cirrhosis and ascites. Terlipressin is recognized as an effective treatment of HRS, but it is expensive and not widely available. Norepinephrine could be an effective alternative. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of norepinephrine compared to terlipressin in the management of HRS.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Effectiveness of norepinephrine versus dopamine for septic shock: a meta analysis

OBJECTIVE: To systematically evaluate the effect of norepinephrine and dopamine on patients with septic shock.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials

BACKGROUND: We performed an updated meta-analysis of noradrenalin reuptake inhibitor (NRI) augmentation therapy in patients with schizophrenia treated with antipsychotics based on a previous meta-analysis (Singh et al.).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis

OBJECTIVES: There has long-been controversy about the possible superiority of norepinephrine compared to dopamine in the treatment of shock. The objective was to evaluate the effects of norepinephrine and dopamine on outcome and adverse events in patients with septic shock.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials

OBJECTIVE: Agomelatine is a new antidepressant with unique melatonin receptor type 1A (MTNR1A) and 1B ( MTNR1B) agonism and serotonergic receptor 5-hydroxytryptamine receptor 2C (5-HT-2C) antagonism. Several studies of patients with major depressive disorder (MDD) have confirmed the superior efficacy and safety of agomelatine in comparison with established treatments, such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). This meta-analysis comprehensively shows the efficacy, acceptability, and safety of agomelatine in comparison with SSRIs and SNRIs used as antidepressants in MDD.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials

The evidence showed superiority of norepinephrine over dopamine for in-hospital or 28-day mortality in critically ill populations with shock in which sepsis was the predominant etiology. With a small caveat regarding the borderline statistical significance of the findings, it appears that the authors' conclusion is reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Bupropion, mirtazapine, and reboxetine in the treatment of depression: Executive summary of final report A05-20C, Version 1.1

The aim of this research is to assess the benefit of treatment with bupropion, mirtazapine or reboxetine in treating the acute phase of depression, in maintenance therapy (relapse prevention), and in recurrence prevention compared to treatment with placebo each other treatment with other antidepressants in each case in adult patients with depression. The focus of the investigation was on patient-relevant outcomes.

Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: May 30, 2011

Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update

OBJECTIVE: To evaluate the efficacy, adverse effect and safety of terlipressin in the treatment of hepatorenal syndrome (HRS).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Quetiapine for bipolar depression: a systematic review and meta-analysis

Quetiapine has been proposed for depression in bipolar patients but a quantitative analysis is lacking. In the present paper, we review and meta-analyze available data about the short-term and long-term efficacy and tolerability of quetiapine for the depressive phase of bipolar disorder or bipolar depression. A literature research was carried out using three electronic databases. Studies providing measures of efficacy and tolerability of quetiapine, either as monotherapy or as augmentation, for bipolar depression were considered. Seven short-term studies and four maintenance studies were included. Short-term studies suggested that patients treated with quetiapine monotherapy were significantly more likely than patients treated with placebo and further active comparators to achieve higher response and remission rates as well as more clinical improvements at the endpoint. Such benefits were significant from the first weeks of treatment onward. Maintenance studies suggested that the combination of quetiapine and mood stabilizers was significantly better than placebo plus mood stabilizers for the prevention of both depressive and manic relapses. Quetiapine was generally well tolerated. Furthermore, several clinical variables moderated outcomes under investigation. In conclusion, quetiapine could have some advantages over traditional treatments for the treatment of bipolar depression.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Drug Class Review: Neuropathic Pain: Final Update 1 Report [Internet]

We compared the effectiveness and harms of anticonvulsants, tricyclic antidepressants, serotonin–norepinephrine reuptake inhibitors (SNRIs), and the lidocaine patchin adults with neuropathic pain.

Drug Class Reviews - Oregon Health & Science University.

Version: June 2011
Show search results within this document

Combination Therapy for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness [Internet]

The aim of this review is to summarize evidence of the clinical effectiveness of combination treatment with long-acting and short-acting stimulant medications to inform decisions around combination use of these drugs for attention deficit hyperactivity disorder (ADHD) in adults.

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: February 23, 2016
Show search results within this document

Systematic Reviews in PubMed

See all (440)...

Systematic Review Methods in PubMed

See all (1)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...